Back

GOG 172

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Date of Publication:

January 5, 2006

Pubmed Link:
https://www.ncbi.nlm.nih.gov/pubmed/16394300
Hypothesis:

Does IP chemotherapy improve overall survival in optimally debulked advanced ovarian cancer patients?

Control Arm(s):

135 mg/m2 Paclitaxel IV, over 24hrs

cisplatin 75mg/m2 IV on day 2

q3wks x6 cycles

Experimental Arm(s):

135 mg/m2 paclitaxel IV, over 24hrs

cisplatin 100 mg/m2 IP day 2

60 mg/m2 Paclitaxel IP day 8

q3wks x6 cycles

Primary End Point:

OS

Inclusion Criteria:

Stage III epithelial ovarian carcinoma

Residual disease ≤1cm

Exclusion Criteria:
Results:

IP/IV vs IV:

median f/u: 48.2 mos

median PFS: 23.8  vs. 18 mos (SS)

median OS: 65.6 vs 49.7 m (SS)

Completed 6 cycles: 42% vs 83% (SS)

G3/4 GI Toxicity: 46% vs 24% (SS)

G3/4 Neutropenia: 76% vs 64% (SS)

G3/4 Neuropathy: 19% vs 9% (SS)

G3/4Fatigue: 18% vs 4% (SS)

Conclusions:

IP/IV chemotherapy resulted in significantly improved PFS and OS in optimally debulked patients with advanced ovarian cancer

Reviewer:
Shitanshu Uppal, OTF